首頁 > 市場調查報告書 > 醫療設備

病患監測

市場調查報告書

商品編碼

2126422

神經基因檢測市場－策略分析與預測（2026-2035）

Neurogenetic Testing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計神經遺傳學檢測市場將從 2026 年的 54.1 億美元成長到 2035 年的 145.8 億美元，複合年成長率為 11.6%。

全球神經遺傳學檢測市場正快速擴張，這主要得益於基因測序技術的進步以及精準神經病學領域對基因診斷認知的不斷提高。該市場透過將基因測序技術與臨床診斷和長期疾病管理相結合，成為精準神經病學的重要組成部分。基因檢測能夠識別導致多種神經系統疾病的遺傳性或新發突變，使醫生能夠做出明確診斷、預測疾病進展、評估遺傳性風險，並篩選出適合接受標靶治療和參與臨床試驗的患者。由於分子檢測尚未普及或延誤，罕見神經系統疾病往往多年無法確診，因此基因檢測的需求持續成長。醫療系統日益認知到，早期基因診斷可以減少不必要的影像檢查、侵入性操作和重複的專科就診。診斷檢測實驗室正在擴展其全面的基因組檢測和定序能力，以縮短檢測週期並提高診斷準確性。隨著基因治療、RNA療法和個人化醫療的進步，神經遺傳學檢測的策略重要性日益凸顯，分子診斷已成為治療方案選擇的必要前提。診斷與治療之間的這種聯繫，正在推動已開發國家和新興國家醫療保健市場對全面神經遺傳學檢測的長期需求。

市場促進因素

神經學領域次世代定序的應用日益廣泛

次世代定序能夠以極高的分析靈敏度同時分析多個基因，是現代神經遺傳診斷的技術基礎。醫療機構正從傳統的順序診斷流程轉向綜合定序策略，以縮短診斷時間。這種轉變減少了重複檢測的次數，同時提高了識別複雜遺傳疾病致病突變的準確性。因此，臨床信心增強，對綜合神經遺傳檢測服務的需求也日益成長。

罕見和遺傳性神經系統疾病負擔日益加重

罕見神經系統疾病雖然每種疾病的盛行率較低，但卻影響著全球整體數百萬人。診斷的不確定性常常導致治療決策延誤，並增加醫療成本。分子診斷能夠提供明確的疾病分類，並指南患者的長期管理，促使醫院擴大基因檢測的覆蓋範圍。因此，臨床實踐中對罕見神經系統疾病的認知不斷提高，也持續推動兒童和成人神經科相關檢測數量的成長。

精準醫療的擴展

在精準醫療中，準確的分子層級表徵對於制定標靶治療至關重要。製藥公司正在開發基因療法和突變特異性療法，這些療法需要在患者入組和治療開始前進行檢驗的基因診斷。這些療法的不斷發展推動了診斷實驗室、臨床醫生和生物技術公司之間的合作，同時也帶來了持續的市場需求。

基因組醫學與臨床實踐的融合正在逐步推進。

醫療機構日益認知到基因組檢測在特定患者群體常規神經系統評估中的重要性。臨床指引支持對遺傳性神經系統疾病進行更廣泛的基因評估，並建議儘早轉診至遺傳學家。這種整合有助於提高檢查室利用率，並改善複雜神經系統疾病的多學科管理。

市場限制因素

全面定序和高級生物資訊學的高成本仍然是保險報銷有限的醫療保健系統的一大障礙。解讀意義不明的突變持續造成臨床複雜性，並需要專業的遺傳學知識。訓練有素的臨床遺傳學家和遺傳諮詢師數量有限，限制了某些地區的檢測能力。此外，對基因組資訊資料隱私的擔憂也會影響病患和醫療服務提供者的接受度。

測試類型
- 單基因檢測
- 基因檢測
- 全EXOME定序（WES）
- 全基因測序（WGS）
- 染色體微陣列分析（CMA）
- 重複擴張試驗
- 粒線體DNA檢測
透過技術
- 次世代定序（NGS）
- 桑格定序
- 基於PCR的檢測
- 基於微陣列的偵測
- 長讀長定定序
疾病適應症
- 癲癇
- 神經肌肉疾病
- 運動障礙
- 神經發育障礙
- 遺傳性共濟失調
- 遺傳性神經病變
- 白質營養不良
- 其他神經遺傳性疾病
依檢體類型
- 血
- 唾液/口腔黏膜拭子
- 組織樣本
- 腦脊髓液（CSF）
- 其他類型的檢體
最終用戶
- 醫院
- 診斷檢查室
- 神經科專科診所
- 學術研究機構
- 參考檢查室

第10章：神經遺傳學檢測市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章神經遺傳學檢測市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Illumina, Inc.
Revvity, Inc.
Quest Diagnostics Incorporated
Labcorp Holdings Inc.
Eurofins Scientific SE
Invitae Corporation
Centogene NV
GeneDx Holdings Corp.
Blueprint Genetics Oy
Fulgent Genetics, Inc.
Natera, Inc.
Oxford Nanopore Technologies plc
BGI Genomics Co., Ltd.
Macrogen, Inc.

第14章神經遺傳學檢測市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009139

The Neurogenetic Testing Market is predicted to increase at a CAGR of 11.6% from a market size of USD 5.41 billion in 2026 to USD 14.58 billion in 2035.

The global neurogenetic testing market is experiencing rapid expansion, driven by advances in genomic sequencing technologies and the growing recognition of genetic diagnosis in precision neurology. This market functions as a critical component of precision neurology by connecting genomic sequencing technologies with clinical diagnosis and long-term disease management. Genetic testing identifies inherited or de novo variants responsible for numerous neurological disorders, allowing physicians to establish definitive diagnoses, estimate disease progression, evaluate familial risk, and identify patients eligible for targeted therapies or clinical trials. Demand continues to increase because rare neurological diseases often remain undiagnosed for years when molecular testing is unavailable or delayed. Healthcare systems are recognizing that earlier genetic diagnosis reduces unnecessary imaging studies, invasive procedures, and repeated specialist consultations. Diagnostic laboratories are expanding comprehensive gene panels and sequencing capabilities to improve turnaround time and increase diagnostic yield. The strategic importance of neurogenetic testing is increasing alongside advances in gene therapies, RNA-based therapeutics, and personalized medicine, making molecular diagnosis an essential prerequisite for therapy selection. This relationship between diagnostics and therapeutics is strengthening long-term demand for comprehensive neurogenetic testing across developed and emerging healthcare markets.

Market Drivers

Increasing Adoption of Next-Generation Sequencing in Neurology

Next-generation sequencing serves as the technological foundation of modern neurogenetic diagnostics because it analyzes multiple genes simultaneously with high analytical sensitivity. Healthcare providers are replacing sequential diagnostic workflows with comprehensive sequencing strategies to shorten diagnostic timelines. This transition reduces repeated testing while improving identification of pathogenic variants across genetically complex disorders. The result is greater clinical confidence and expanding demand for comprehensive neurogenetic testing services.

Rising Burden of Rare and Inherited Neurological Disorders

Rare neurological diseases collectively affect millions of individuals worldwide despite the low prevalence of individual conditions. Diagnostic uncertainty frequently delays treatment decisions and increases healthcare costs. Hospitals are expanding access to genetic testing because molecular diagnosis provides definitive disease classification and informs long-term patient management. Improved clinical awareness therefore continues to strengthen testing volumes across pediatric and adult neurology.

Expansion of Precision Medicine

Precision medicine depends on accurate molecular characterization before targeted therapies can be prescribed. Pharmaceutical companies are developing gene therapies and mutation-specific treatments that require validated genetic diagnoses before patient enrollment or treatment initiation. This therapeutic evolution is increasing collaboration between diagnostic laboratories, clinicians, and biotechnology companies while reinforcing sustained market demand.

Growing Clinical Integration of Genomic Medicine

Healthcare institutions increasingly recognize genomic testing as part of routine neurological evaluation for selected patient populations. Clinical guidelines are supporting broader genetic evaluation for inherited neurological disorders, encouraging earlier referrals to genetic specialists. This integration strengthens laboratory utilization while improving multidisciplinary management of complex neurological diseases.

Market Restraints

High costs associated with comprehensive sequencing and advanced bioinformatics remain a barrier in healthcare systems with limited reimbursement. Interpretation of variants of uncertain significance continues to create clinical complexity and requires specialized genetic expertise. Limited availability of trained clinical geneticists and genetic counselors restricts testing capacity in several regions. Additionally, data privacy concerns regarding genomic information can influence patient and provider acceptance.

Technology and Segment Insights

By Test Type

Single-gene testing remains clinically relevant for neurological disorders with well-established monogenic causes and characteristic phenotypes. Gene panel testing is increasingly utilized for disorders with significant genetic heterogeneity, offering a balanced approach between cost and comprehensiveness. Whole exome sequencing (WES) and whole genome sequencing (WGS) provide the broadest genomic coverage, improving diagnostic yield for complex or atypical presentations. Chromosomal microarray analysis (CMA) detects copy number variations. Repeat expansion testing is essential for disorders involving nucleotide repeat expansions. Mitochondrial DNA testing identifies variants in the mitochondrial genome.

By Technology

Next-generation sequencing serves as the dominant technology platform because it combines high analytical throughput with broad genomic coverage. Clinical laboratories are expanding NGS capacity to accommodate growing testing demand while improving workflow automation. Sanger sequencing remains important for targeted variant confirmation and familial segregation analysis. PCR-based testing provides rapid, cost-effective analysis for specific mutations. Microarray-based testing enables high-throughput copy number analysis. Long-read sequencing is emerging as a valuable tool for resolving complex genomic regions and repeat expansions.

By Disease Indication

Epilepsy represents a major disease indication because numerous inherited epileptic syndromes demonstrate identifiable molecular causes. Neurologists are requesting comprehensive gene panels and exome sequencing earlier in the diagnostic pathway to support treatment selection and prognosis. Neuromuscular disorders, movement disorders, neurodevelopmental disorders, hereditary ataxias, hereditary neuropathies, and leukodystrophies are additional indications driving demand for neurogenetic testing. Earlier molecular confirmation reduces unnecessary investigations while facilitating access to precision therapies and clinical research.

By End User

Hospitals represent a significant end-user segment, integrating genetic testing into neurology departments and multidisciplinary clinics. Diagnostic laboratories are the primary service providers, offering comprehensive testing panels and interpretation. Specialty neurology clinics are increasingly utilizing genetic testing for targeted patient populations. Academic and research institutes contribute to test development and clinical validation. Reference laboratories provide specialized testing services for complex cases.

Competitive and Strategic Outlook

The competitive landscape features major diagnostic companies and specialized genomic testing providers. F. Hoffmann-La Roche Ltd. maintains a strong strategic position through its integrated diagnostics portfolio and expertise in molecular medicine, combining advanced sequencing technologies with digital healthcare solutions. Illumina, Inc. is a global leader in next-generation sequencing technologies, providing instruments, reagents, and bioinformatics that form the foundation of many neurogenetic testing workflows. Revvity, Inc. leverages its expertise in genomics and molecular diagnostics to support genetic testing for rare diseases. Quest Diagnostics Incorporated and Labcorp Holdings Inc. operate large diagnostic laboratory networks providing broad access to neurogenetic testing services. Eurofins Scientific SE offers a broad portfolio of molecular diagnostic services. Invitae Corporation and GeneDx Holdings Corp. focus on comprehensive genetic testing for rare inherited diseases, with expertise in exome and genome sequencing.
Strategic developments include increasing integration of artificial intelligence for variant interpretation, expansion of long-read sequencing capabilities, and development of comprehensive genomic databases. Companies are forming partnerships with healthcare providers, academic institutions, and pharmaceutical developers to improve testing workflows and support therapeutic development. Product launches focus on expanded gene panels, advanced bioinformatics platforms, and automated laboratory workflows. Companies that successfully combine advanced sequencing technologies, robust bioinformatics, and clinical expertise are expected to maintain competitive leadership.

Conclusion

The neurogenetic testing market is poised for substantial growth, driven by advances in sequencing technologies, the expansion of precision medicine, and increasing clinical integration of genomic testing. The evolution from a specialized diagnostic service toward a core component of neurological practice is reshaping the market. Companies that successfully deliver comprehensive, clinically validated, and interpretable genomic testing solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding healthcare infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Neurogenetic Testing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Neurogenetic Disease Classification
3.8 Disease Burden & Unmet Clinical Needs
3.9 Epidemiology & Disease Prevalence Analysis
3.10 Diagnosed Patient Population Analysis
3.11 Genetic Testing Adoption Analysis
3.12 Clinical Testing Landscape

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 AI Integration in Neurogenetic Testing
6.6 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Neurogenetic Testing Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Test Type
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology
8.6 Analysis by End User

9. Neurogenetic Testing Market Segment Analysis (2021-2035)

9.1 By Test Type
- 9.1.1 Single-Gene Testing
- 9.1.2 Gene Panel Testing
- 9.1.3 Whole Exome Sequencing (WES)
- 9.1.4 Whole Genome Sequencing (WGS)
- 9.1.5 Chromosomal Microarray Analysis (CMA)
- 9.1.6 Repeat Expansion Testing
- 9.1.7 Mitochondrial DNA Testing
9.2 By Technology
- 9.2.1 Next-Generation Sequencing (NGS)
- 9.2.2 Sanger Sequencing
- 9.2.3 PCR-Based Testing
- 9.2.4 Microarray-Based Testing
- 9.2.5 Long-Read Sequencing
9.3 By Disease Indication
- 9.3.1 Epilepsy
- 9.3.2 Neuromuscular Disorders
- 9.3.3 Movement Disorders
- 9.3.4 Neurodevelopmental Disorders
- 9.3.5 Hereditary Ataxias
- 9.3.6 Hereditary Neuropathies
- 9.3.7 Leukodystrophies
- 9.3.8 Other Neurogenetic Disorders
9.4 By Sample Type
- 9.4.1 Blood
- 9.4.2 Saliva/Buccal Swab
- 9.4.3 Tissue Samples
- 9.4.4 Cerebrospinal Fluid (CSF)
- 9.4.5 Other Sample Types
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Diagnostic Laboratories
- 9.5.3 Specialty Neurology Clinics
- 9.5.4 Academic & Research Institutes
- 9.5.5 Reference Laboratories